Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvitegravir/ritonavir versus raltegravir with optimized background regimen in treatment-experienced adults with HIV-1
NL-OMON33886Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Elvitegravir/ritonavir plus background regimen with Raltegravir plus background regimen (2 arms). Primary endpoint: Primary efficacy endpoint. Started Mar 2009; status: active, not recruiting.
02
Drugs
elvitegravirritonavirraltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON33886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33886.